Pasithea Therapeutics (KTTA) announced the appointment of Kartik Krishnan as chief medical officer of the company, effective May 1. Krishnan will oversee all clinical development and medical strategy as the company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 associated plexiform and cutaneous neurofibromas. Prior to joining Pasithea, Krishnan was CEO at OncoNano Medicines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA: